

Anti-TNF- α (Humicade) Biotinylated Antibody

08/20

CATALOG NO.: A2182-50 (50 μ g)

BACKGROUND DESCRIPTION: Recombinant monoclonal antibody to TNF- α . Manufactured using recombinant technology with variable regions (i.e. specificity) from the hybridoma CDP 571 (Humicade). The antibody binds specifically to TNF- α , a pro-inflammatory cytokine that stimulates the release of other cytokines e.g. IL-1, IL-6, and GM-CSF as well as secretion of ICAM-1 and VCAM-1 from endothelial cells. It stimulates acute phase responses and acts as a chemoattractant for NK cells and monocytes/macrophages. The antibody reached Phase II clinical trials with Celltech, UCB.

ALTERNATE NAMES: BAY 103356, BAY W 3356, CDP 571, DIF, TNFA, TNFSF2, TNLG1F, TNF-alpha, APC1 Protein

ANTIBODY TYPE: Monoclonal

CLONE: CDP571

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human TNF- α

PURIFICATION: Affinity purified using protein A

FORM: Liquid


FORMULATION: In PBS, pH 7.2, 30% glycerol, 0.5% BSA, 0.5 mM EDTA and 0.03% proclin

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -20°C. Avoid repeated freeze/thaw cycles

APPLICATIONS AND USAGE: ELISA 0.1 μ g - 1 μ g/ml

This information is only intended as a guide. The optimal dilutions must be determined by the user



Direct ELISA shows that Anti-TNF- α (Humicade) Biotinylated antibody can bind to immobilized recombinant human TNF- α with a linear range of 0-5 ng/ml.

RELATED PRODUCTS:

Anti-TNF alpha (Humicade), Human IgG4 Antibody (A1093)
 Anti-TNF- α (Golimumab), Human IgG1 Antibody (A2141)
 Anti-TNF- α (Certolizumab Pegol), Humanized Antibody (A2142)
 Anti-TNF- α (Adalimumab), humanized Antibody (A1048)
 Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

FOR RESEARCH USE ONLY! Not to be used on humans.